Ivabradine-Flecainide as Breakthrough Drug Combination for Congenital Junctional Ectopic Tachycardia: A Case Report and Literature Review
Congenital junctional ectopic tachycardia (CJET) is a rare tachyarrhythmia that remains difficult to manage, with suboptimal control in most cases. Here, we report literature research on the use of ivabradine in the treatment of pediatric junctional ectopic tachycardia (JET), both congenital and pos...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Llibre |
| Publicat: |
MDPI AG,
2021-11-01T00:00:00Z.
|
| Matèries: | |
| Accés en línia: | Connect to this object online. |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_b19a283d61e546e4a27ac43d39d00d4b | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Giovanni Maria Di Marco |e author |
| 700 | 1 | 0 | |a Angelica De Nigris |e author |
| 700 | 1 | 0 | |a Angela Pepe |e author |
| 700 | 1 | 0 | |a Annamaria Pagano |e author |
| 700 | 1 | 0 | |a Giangiacomo Di Nardo |e author |
| 700 | 1 | 0 | |a Vincenzo Tipo |e author |
| 245 | 0 | 0 | |a Ivabradine-Flecainide as Breakthrough Drug Combination for Congenital Junctional Ectopic Tachycardia: A Case Report and Literature Review |
| 260 | |b MDPI AG, |c 2021-11-01T00:00:00Z. | ||
| 500 | |a 10.3390/pediatric13040074 | ||
| 500 | |a 2036-7503 | ||
| 520 | |a Congenital junctional ectopic tachycardia (CJET) is a rare tachyarrhythmia that remains difficult to manage, with suboptimal control in most cases. Here, we report literature research on the use of ivabradine in the treatment of pediatric junctional ectopic tachycardia (JET), both congenital and postoperative, and describe the successful use of ivabradine-flecainide association for CJET therapy resistant to other antiarrhythmic agents. This new drug combination was effective in completely suppressing JET. Ivabradine-flecainide combination may be considered a new therapeutic strategy of CJET with a satisfactory efficacy/tolerability ratio in patients resistant to conventional drug combinations. | ||
| 546 | |a EN | ||
| 690 | |a ivabradine | ||
| 690 | |a tachycardia | ||
| 690 | |a junctional | ||
| 690 | |a pediatrics | ||
| 690 | |a congenital | ||
| 690 | |a Medicine | ||
| 690 | |a R | ||
| 690 | |a Pediatrics | ||
| 690 | |a RJ1-570 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Pediatric Reports, Vol 13, Iss 4, Pp 624-631 (2021) | |
| 787 | 0 | |n https://www.mdpi.com/2036-7503/13/4/74 | |
| 787 | 0 | |n https://doaj.org/toc/2036-7503 | |
| 856 | 4 | 1 | |u https://doaj.org/article/b19a283d61e546e4a27ac43d39d00d4b |z Connect to this object online. |